Acumen appoints Dr. James Doherty as President and Chief Development Officer

Acumen Pharmaceuticals, Inc.

Dr. James Doherty appointed President and Chief Development Officer effective Feb 1, 2024, reporting to CEO Daniel O'Connell.
Doherty previously served as Chief Development Officer at Sage Therapeutics, contributing to two FDA approvals for postpartum depression.
He will oversee clinical/non-clinical development, CMC, and regulatory functions as Acumen prepares to initiate ALTITUDE-AD study for ACU193.
Daniel O'Connell's title changes to CEO (previously CEO and President) as Doherty assumes the President role.
Doherty led Alzheimer's research at AstraZeneca and holds a Ph.D. in Neurobiology from Georgetown University.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

James Doherty

President and Chief Development Officer

ABOS · Acumen Pharmaceuticals, Inc.

Effective: 2024-02-01
Filed: February 1, 2024, 6:59 PM ET

James Doherty has been appointed as its President and Chief Development Officer, effective February 1, 2024.

Role change

Daniel O'Connell

Chief Executive Officer

ABOS · Acumen Pharmaceuticals, Inc.

Effective: 2024-02-01
Successor: James Doherty
Filed: February 1, 2024, 6:59 PM ET

Effective upon the commencement of Mr. Doherty's employment, Daniel O'Connell's position would be updated to Chief Executive Officer.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

James Doherty was appointed as President and Chief Development Officer at Acumen Pharmaceuticals, Inc..

Action: appointed
Role: President and Chief Development Officer

Exact text from the filing

James Doherty has been appointed as its President and Chief Development Officer, effective February 1, 2024.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Daniel O'Connell changed role as Chief Executive Officer at Acumen Pharmaceuticals, Inc..

Action: updated
Role: Chief Executive Officer

Exact text from the filing

Effective upon the commencement of Mr. Doherty's employment, Daniel O'Connell's position would be updated to Chief Executive Officer.

View on SEC.gov

Acumen Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001576885-24-000032

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.